These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 27669017)

  • 1. High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors.
    Becker DL; Chit A; DiazGranados CA; Maschio M; Yau E; Drummond M
    Hum Vaccin Immunother; 2016 Dec; 12(12):3036-3042. PubMed ID: 27669017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial.
    Chit A; Becker DL; DiazGranados CA; Maschio M; Yau E; Drummond M
    Lancet Infect Dis; 2015 Dec; 15(12):1459-66. PubMed ID: 26362172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines.
    DiazGranados CA; Robertson CA; Talbot HK; Landolfi V; Dunning AJ; Greenberg DP
    Vaccine; 2015 Sep; 33(38):4988-93. PubMed ID: 26212007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty.
    DiazGranados CA; Dunning AJ; Robertson CA; Talbot HK; Landolfi V; Greenberg DP
    Vaccine; 2015 Aug; 33(36):4565-71. PubMed ID: 26187260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors.
    Chit A; Roiz J; Briquet B; Greenberg DP
    Vaccine; 2015 Jan; 33(5):734-41. PubMed ID: 25444791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Previous-Year Vaccination on the Efficacy, Immunogenicity, and Safety of High-Dose Inactivated Influenza Vaccine in Older Adults.
    DiazGranados CA; Dunning AJ; Robertson CA; Talbot HK; Landolfi V; Greenberg DP
    Clin Infect Dis; 2016 May; 62(9):1092-1099. PubMed ID: 26908801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools (RELATIVES) pilot study: a cluster randomized trial.
    Kwong JC; Pereira JA; Quach S; Pellizzari R; Dusome E; Russell ML; Hamid JS; Feinberg Y; Winter AL; Gubbay JB; Sirtonski B; Moher D; Sider D; Finkelstein M; Loeb M;
    Vaccine; 2015 Jan; 33(4):535-41. PubMed ID: 25488331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of high-dose versus standard-dose influenza vaccine in older adults.
    DiazGranados CA; Dunning AJ; Kimmel M; Kirby D; Treanor J; Collins A; Pollak R; Christoff J; Earl J; Landolfi V; Martin E; Gurunathan S; Nathan R; Greenberg DP; Tornieporth NG; Decker MD; Talbot HK
    N Engl J Med; 2014 Aug; 371(7):635-45. PubMed ID: 25119609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults.
    Raviotta JM; Smith KJ; DePasse J; Brown ST; Shim E; Nowalk MP; Wateska A; France GS; Zimmerman RK
    Vaccine; 2017 Oct; 35(42):5708-5713. PubMed ID: 28890196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative and Absolute Effectiveness of High-Dose and Standard-Dose Influenza Vaccine Against Influenza-Related Hospitalization Among Older Adults-United States, 2015-2017.
    Doyle JD; Beacham L; Martin ET; Talbot HK; Monto A; Gaglani M; Middleton DB; Silveira FP; Zimmerman RK; Alyanak E; Smith ER; Flannery BL; Rolfes M; Ferdinands JM
    Clin Infect Dis; 2021 Mar; 72(6):995-1003. PubMed ID: 32067049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluzone® High-Dose Influenza Vaccine.
    Robertson CA; DiazGranados CA; Decker MD; Chit A; Mercer M; Greenberg DP
    Expert Rev Vaccines; 2016 Dec; 15(12):1495-1505. PubMed ID: 27813430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of high-dose inactivated influenza vaccine in adults aged ≥65 years: A systematic literature review.
    Colrat F; Thommes E; Largeron N; Alvarez FP
    Vaccine; 2021 Mar; 39 Suppl 1():A42-A50. PubMed ID: 33518466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost Effectiveness of Influenza Vaccine for U.S. Children: Live Attenuated and Inactivated Influenza Vaccine.
    Shim E; Brown ST; DePasse J; Nowalk MP; Raviotta JM; Smith KJ; Zimmerman RK
    Am J Prev Med; 2016 Sep; 51(3):309-17. PubMed ID: 27079638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools (RELATIVES) cluster randomized trial: Pilot results from a household surveillance study to assess direct and indirect protection from influenza vaccination.
    Kwong JC; Pereira JA; Quach S; Pellizzari R; Dusome E; Russell ML; Hamid JS; Feinberg Y; Winter AL; Gubbay JB; Sirtonski B; Moher D; Sider D; Finkelstein M; Loeb M;
    Vaccine; 2015 Sep; 33(38):4910-5. PubMed ID: 26232348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
    Luce BR; Nichol KL; Belshe RB; Frick KD; Li SX; Boscoe A; Rousculp MD; Mahadevia PJ
    Vaccine; 2008 Jun; 26(23):2841-8. PubMed ID: 18462851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis.
    Izurieta HS; Thadani N; Shay DK; Lu Y; Maurer A; Foppa IM; Franks R; Pratt D; Forshee RA; MaCurdy T; Worrall C; Howery AE; Kelman J
    Lancet Infect Dis; 2015 Mar; 15(3):293-300. PubMed ID: 25672568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of high-dose versus standard-dose influenza vaccination in community-dwelling veterans.
    Richardson DM; Medvedeva EL; Roberts CB; Linkin DR;
    Clin Infect Dis; 2015 Jul; 61(2):171-6. PubMed ID: 25829001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of inactivated influenza vaccination in children with medical risk conditions in the Netherlands.
    Naber SK; Bruijning-Verhagen PCJL; de Hoog MLA; van Giessen A
    Vaccine; 2020 Apr; 38(17):3387-3396. PubMed ID: 32115297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
    DiazGranados CA; Saway W; Gouaux J; Baron M; Baker J; Denis M; Jordanov E; Landolfi V; Yau E
    Vaccine; 2015 Dec; 33(51):7188-7193. PubMed ID: 26555348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost Benefit of High-Dose vs Standard-Dose Influenza Vaccine in a Long-Term Care Population During an A/H1N1-Predominant Influenza Season.
    Shireman TI; Ogarek J; Gozalo P; Zhang T; Mor V; Davidson HE; Han L; Taljaard M; Gravenstein S
    J Am Med Dir Assoc; 2019 Jul; 20(7):874-878. PubMed ID: 30777631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.